333 Phase I dose-escalation trial with the DNA-alkylating anti-HER2 antibody-drug conjugate SYD985. (September 2015) - Van Herpen, C.M.; Banerji, U.; Mommers, E.C.; Koper, N.P.; Goedings, P.; Lopez, J.; Awada, A.; Fiebrich, H.B.; Aftimos, P.G.